← All sarcoma trials
Recruiting now—Ages 18 Years to 65 Years

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

Sponsor: Ain Shams University · NCT07057765 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

DLBCL - Diffuse Large B Cell LymphomaMarkers of Inflammation

What it tests

  • Observational Assessment of Standard R-CHOP Treatmentdrug

Where it's running1 site

1 international site

  • Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University

    Cairo, Cairo Governorate, Egypt 1181

    Recruiting now
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Age ≥ 18 years and ≤ 65 years
* Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL)
* Any stage of disease (nodal or extra-nodal), with or without B symptoms
* Scheduled to receive standard systemic treatment (R-CHOP)
* ECOG performance status 0-2
* Baseline normal:
* Complete blood count (CBC)
* Hepatitis viral markers
* Liver and renal function tests
* Urine analysis
* Echocardiogram
* Additional investigations to exclude current infection if clinically indicated

Exclusion Criteria:

* History of other concurrent or previous malignancies
* Relapsed or refractory DLBCL
* Uncontrolled comorbid conditions that may interfere with study participation, including:
* Diabetes mellitus
* Autoimmune diseases
* Active infections
* Chronic inflammatory diseases
* Cardiac dysfunction
* Liver cell failure
* Pregnant females

Updated 2025-07-10 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.